http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html si-local-file:///var/storage/secattach/20260805/26869471.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html si-local-file:///var/storage/secattach/20260805/26869471.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html si-local-file:///var/storage/secattach/20260805/26869471.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BeOne+Medicines+Ltd.++++++For%3A+Aug+05/26869471.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html si-local-file:///var/storage/secattach/20260805/26869492.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html si-local-file:///var/storage/secattach/20260805/26869492.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html si-local-file:///var/storage/secattach/20260805/26869492.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+30/26869492.html Wed, 05 Aug 2026 06:05:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html <ul class="bwlistdisc"> <li> <i>Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year </i> </li> <li> <i>BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year</i> </li> <li> <i>Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter</i> </li> <li> <i>Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion</i> </li> </ul> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54583421&amp;newsitemid=20260805570642&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=042cab67e638c8c60542ea3f9888c9e5" shape="rect">BeOne Medicines Ltd.</a> http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Second+Quarter+2026+Financial+Results+and+Business+Updates/26869183.html Wed, 05 Aug 2026 06:00:00 -0400 06160 688235 A.06822034 O.20026344 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html si-local-file:///var/storage/secattach/20260803/26859352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html Mon, 03 Aug 2026 17:18:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html si-local-file:///var/storage/secattach/20260803/26859352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html Mon, 03 Aug 2026 17:18:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html si-local-file:///var/storage/secattach/20260803/26859352.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jul+30++Filed+by%3A+Lee+Chan+Henry/26859352.html Mon, 03 Aug 2026 17:18:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html si-local-file:///var/storage/secattach/20260803/26858958.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html Mon, 03 Aug 2026 16:51:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html si-local-file:///var/storage/secattach/20260803/26858958.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html Mon, 03 Aug 2026 16:51:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html si-local-file:///var/storage/secattach/20260803/26858958.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Rosenberg+Aaron/26858958.html Mon, 03 Aug 2026 16:51:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Lee+Chan+Henry/26845011.html si-local-file:///var/storage/secattach/20260730/26845011.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Lee+Chan+Henry/26845011.html Thu, 30 Jul 2026 17:34:00 -0400 688235 BEIGF O.76306903